^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
04/09/2021
Excerpt:
Regimens for Ph-positive B-ALL...option added: Blinatumomab ± TKI
Source:
Published date:
04/09/2021
Excerpt:
Regimens for Ph-positive B-ALL...option added: Blinatumomab ± TKI
Secondary therapy:
Tyrosine Kinase Inhibitors
Source:
Title:
4243 Reduced-Dose Chemotherapy Followed By Blinatumomab As Induction Therapy in Treatment of Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia - Interim Results from a Multicenter, Single-Arm, Phase 2 Study
Published date:
11/02/2023
Excerpt:
These preliminary results indicate that the reduced intensity chemotherapy followed by blinatumomab is an effective regimen in adults with newly diagnosed Ph-negative BCP-ALL, resulting in favorable response rates, deep remission, and low-grade treatment-related AEs. These promising findings may provide a rationale for integrating blinatumomab into future induction therapy recommendations.
Secondary therapy:
Chemotherapy
Trial ID:
Source:
Title:
Blinatumomab with Tyrosine Kinase Inhibitor for Ph-Positive B-Acute Lymphoblastic Leukemia (B-ALL): Multicenter Retrospective Review
Published date:
11/02/2023
Excerpt:
A retrospective review of adolescents and adults (14 years or older) with Ph-positive B-ALL patients who received blinatumomab with TKI...In 3 patients with LBP-CML, two patients achieved complete molecular response (CMR) using PCR for BCR::ABL, and one patient achieved MMR (0.036%)....Although with short follow-up, combining TKI with blinatumomab seems to have a high complete molecular response rate in patients with newly diagnosed and relapsed/refractory Ph-positive B-ALL.
DOI:
https://doi.org/10.1182/blood-2023-180221
Source:
Title:
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
Excerpt:
Single-agent blinatumomab showed antileukemia activity in high-risk patients with Ph+ ALL who had relapsed or were refractory to TKIs...
DOI:
10.1200/JCO.2016.69.3531
Source:
Title:
Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Excerpt:
Twenty of the 21 patients enrolled were evaluable for assessment of the primary end point MRD response...Thirteen of 15 patients with BCR-ABL–negative B-lineage ALL (one of two with MLL-AF4), and three of five patients with BCR-ABL–positive B-lineage ALL responded...Thus blinatumomab is clinically active in molecularly refractory B-lineage ALL patients with high MRD burden....Probability for relapse-free survival is 78% at a median follow-up of 405 days....In summary, blinatumomab seems to offer a novel and efficacious treatment for MRD-positive B-lineage ALL and results in prolonged leukemia-free survival.
DOI:
10.1200/JCO.2010.32.7270
Trial ID:
